Summary of interphase FISH results of Amp1q21 in patients with MGUS, SMM, newly diagnosed MM, and relapsed MM
. | Amp1q21 (%) . |
|---|---|
| MGUS | |
| Total | 0/14 (0) |
| Progression, + | 0/1 (0) |
| Progression, – | 0/13 (0) |
| SMM | |
| Total | 14/31 (45) |
| Progression, + | 10/12 (83) |
| Progression, – | 4/19 (21) |
| MM | |
| At diagnosis | 205/479 (43) |
| At relapse | 33/45 (72) |
. | Amp1q21 (%) . |
|---|---|
| MGUS | |
| Total | 0/14 (0) |
| Progression, + | 0/1 (0) |
| Progression, – | 0/13 (0) |
| SMM | |
| Total | 14/31 (45) |
| Progression, + | 10/12 (83) |
| Progression, – | 4/19 (21) |
| MM | |
| At diagnosis | 205/479 (43) |
| At relapse | 33/45 (72) |
The median follow-up of patients with MGUS and SMM was 22 months (range, 1 to 88) and 47 months (range, 1 to 123), respectively. P < .001 for SMM progression, +, versus SMM progression, –. P < .001 for MM at diagnosis versus MM at relapse. P = .002 for total MGUS versus total MM
NA indicates not applicable